What caused TSHA's Q2 2024 EPS to fall short of forecasts?

Taysha Gene Therapies, Inc. (TSHA) experienced a shortfall in its estimated EPS for Q2 2024, primarily due to a combination of factors:

1. **Revenue Lagging Expectations**: While TSHA's quarterly revenue was reported at $3.41 million, which was slightly below the analyst estimates of $3.70 million. This shortfall, although relatively small, contributed to the overall EPS shortfall.
2. **Overhead Costs and Expenses**: The company faced significant overhead costs and expenses, which negatively impacted its net margin and return on equity. With a negative net margin of 833.60% and a negative return on equity of 782.81%, TSHA struggled to maintain profitability despite its revenue generation efforts.

In summary, Taysha Gene Therapies' Q2 2024 EPS fell short of forecasts due to a combination of revenue lagging expectations and significant overhead costs and expenses.